Spots Global Cancer Trial Database for phase ii
Every month we try and update this database with for phase ii cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML) | NCT00486265 | Acute Myelogeno... | AZD4877 | 18 Years - | AstraZeneca | |
| A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) | NCT02356991 | Non-Small Cell ... | Famitinib Placebo | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma | NCT01472198 | Pancreatic Canc... | Simtuzumab Gemcitabine Placebo to matc... | 18 Years - | Gilead Sciences | |
| Cognitive and Behavioral Intervention for the Management of Episodic Breathlessness in Patients With Advanced Disease | NCT04630743 | Dyspnea Respiratory Ins... Neoplasms Pulmonary Disea... Lung Diseases Heart Failure Lung Diseases, ... Palliative Care Palliative Medi... Breathlessness | Cognitive and B... | 18 Years - | University of Cologne | |
| 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma | NCT01277406 | Advanced Colore... | 4SC-201(Resmino... FOLFIRI | 18 Years - | 4SC AG | |
| Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD) | NCT00862836 | Ovarian Cancer | Vandetanib | 18 Years - | Sanofi | |
| Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma | NCT01037478 | Hodgkin's Lymph... | Resminostat (4S... | 18 Years - | 4SC AG | |
| Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan | NCT01464411 | Leukemia, Myelo... Myelogenous Leu... | 20 Months - | Kanto CML Study Group | ||
| Phase II Study With Catumaxomab in Patients With Gastric Cancer After Neoadjuvant CTx and Curative Resection | NCT00464893 | Gastric Cancer Gastric Adenoca... | Catumaxomab catumaxomab | 18 Years - | Neovii Biotech | |
| Phase II Lung Metcore - Preoperative Metformin for Lung Cancer | NCT03086733 | Non Small Cell ... Lung Cancer | Metformin | 18 Years - 90 Years | University Health Network, Toronto | |
| Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | NCT02124707 | Head and Neck C... Squamous Cell C... | Cetuximab Paclitaxel Carboplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme | NCT00730262 | Glioblastoma Mu... | TLN-4601 | 18 Years - | Thallion Pharmaceuticals | |
| A Phase II Study of Spinal Radiosurgery | NCT00573872 | Neoplasm Arteriovenous M... | Radiosurgery | 19 Years - | University of Alabama at Birmingham | |
| Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours | NCT00264004 | Tumors | AZD2171 | 18 Years - | AstraZeneca | |
| Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer | NCT01735071 | Ovarian Epithel... | bevacizumab and... bevacizumab, tr... | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments | NCT05152472 | Unresectable Ga... Locally Advance... Metastatic Gast... | Atezolizumab 12... Imatinib 400 MG | 18 Years - | Centre Leon Berard | |
| S 81694 Plus Paclitaxel in Metastatic Breast Cancer | NCT03411161 | Metastatic Brea... Metastatic Trip... | Combination the... Paclitaxel Combination the... | 18 Years - | Servier | |
| Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) | NCT03150004 | Acute Myeloid L... Myelodysplastic... | Cladribine, Cyt... Cladribine and ... | 18 Years - | Medical College of Wisconsin | |
| Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma | NCT03520985 | Refractory Mult... | Pomalidomide Dexamethasone | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma | NCT00250796 | Liver Cancer | Thalidomide, al... Thalidomide, in... | 18 Years - | University of New Mexico | |
| Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma | NCT00199901 | Melanoma | NY-ESO-1 ISCOMA... ISCOMATRIX® adj... | 18 Years - | Ludwig Institute for Cancer Research | |
| Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer | NCT01523457 | Metastatic Panc... Pancreatic Canc... | Folfirinox | 18 Years - | Yale University | |
| FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer | NCT01688336 | Pancreatic Canc... | FOLFIRINOX | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) | NCT00250068 | Lung Diseases Cancer | Liposomal 9-Nit... | 18 Years - | University of New Mexico | |
| Paclitaxel and Capecitabine in Patients With Metastatic/Recurrence Esophageal Cancer | NCT00453323 | Esophageal Canc... | Paclitaxel Capecitabine | 18 Years - | National Cancer Center, Korea | |
| Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma | NCT00297258 | Sarcoma, Soft T... | pazopanib | 21 Years - | GlaxoSmithKline | |
| Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) | NCT00722592 | Ovarian Cancer | Vintafolide pegylated lipos... EC20 | 18 Years - | Endocyte | |
| A Phase II Study of Spinal Radiosurgery | NCT00573872 | Neoplasm Arteriovenous M... | Radiosurgery | 19 Years - | University of Alabama at Birmingham | |
| A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia | NCT00431873 | Lymphocytic Leu... | MGCD0103 | 18 Years - | Mirati Therapeutics Inc. | |
| Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases | NCT01508000 | Colorectal Canc... Liver Metastase... KRAS Wild Type ... | FOLFOX6 Bevacizumab Panitumumab Surgery | 18 Years - 75 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer | NCT00001239 | Breast Cancer Breast Neoplasm... | FLAC with GM-CS... | - | National Institutes of Health Clinical Center (CC) | |
| A Phase II Study of Spinal Radiosurgery | NCT00573872 | Neoplasm Arteriovenous M... | Radiosurgery | 19 Years - | University of Alabama at Birmingham | |
| Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC | NCT04765709 | Non-small Cell ... | durvalumab plus... Durvalumab plus... durvalumab | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence | NCT04797000 | Myelodysplastic... | Eltrombopag Placebo | 20 Years - 99 Years | Novartis | |
| A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer | NCT01270386 | Non-Small-Cell ... | apatinib placebo | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma | NCT00843037 | Paraganglioma Pheochromocytom... | Sunitinib | 18 Years - | University Health Network, Toronto | |
| Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer | NCT00979641 | Neoplasms | Docetaxel | 18 Years - | Tampere University Hospital | |
| A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer | NCT00156884 | Hormone Refract... Bone Metastases | strontium-89 cisplatin | 18 Years - | AHS Cancer Control Alberta | |
| Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases | NCT04001725 | Brain Metastase... Melanoma Lung Cancer Breast Cancer | Dexamethasone Metformin | 18 Years - 75 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer | NCT01523457 | Metastatic Panc... Pancreatic Canc... | Folfirinox | 18 Years - | Yale University | |
| Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma | NCT00199901 | Melanoma | NY-ESO-1 ISCOMA... ISCOMATRIX® adj... | 18 Years - | Ludwig Institute for Cancer Research | |
| Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01) | NCT00625573 | Colorectal Canc... | Abraxane | 18 Years - 90 Years | Mt. Sinai Medical Center, Miami | |
| Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia | NCT00660036 | Acute Myeloid L... | Gemtuzumab ozog... Mitoxantrone Etoposide | 18 Years - 70 Years | University of Pittsburgh | |
| Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma | NCT02863055 | Malignant Pleur... | Nintedanib Placebo | 18 Years - 90 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma | NCT00130442 | Melanoma | PI-88 and dacar... dacarbazine or ... | 18 Years - | Cellxpert Biotechnology Corp. | |
| Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib | NCT02607332 | Gastrointestina... | Paclitaxel | 20 Years - | Asan Medical Center | |
| A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin | NCT00268853 | Diffuse Large-C... | CPOP-R CHOP-R | 18 Years - | CTI BioPharma | |
| Oxaliplatin and Docetaxel for Recurrent or Metastatic Head and Neck Cancer | NCT00557206 | Neoplasms Head and Neck N... | Oxaliplatin and... | 18 Years - | Minneapolis Veterans Affairs Medical Center | |
| Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma | NCT00250796 | Liver Cancer | Thalidomide, al... Thalidomide, in... | 18 Years - | University of New Mexico | |
| Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) | NCT03150004 | Acute Myeloid L... Myelodysplastic... | Cladribine, Cyt... Cladribine and ... | 18 Years - | Medical College of Wisconsin | |
| 1st Line Durvalumab in PS 2 NSCLC Patients | NCT03620669 | NSCLC Stage IV NSCLC Stage III... | Durvalumab | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | NCT00813072 | Stomach Neoplas... Esophageal Neop... | PEP02 irinotecan docetaxel | 18 Years - | PharmaEngine | |
| Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases | NCT00910728 | Primary Myelofi... Post-Polycythae... Essential Throm... | AZD1480 | 25 Years - 99 Years | AstraZeneca | |
| E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | NCT01271504 | Hepatocellular ... | Sorafenib Sorafenib | 18 Years - | Eisai Inc. | |
| Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer | NCT00138918 | Prostate Cancer | OGX-011 | 18 Years - | University of British Columbia | |
| Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer | NCT01172925 | NSCLC Dyspnea | Tiotropium Placebo | 18 Years - | McMaster University | |
| Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | NCT00278889 | Colorectal Canc... | AZD2171 5-fluorouracil Leucovorin Oxaliplatin Bevacizumab | 18 Years - | AstraZeneca | |
| Niraparib Efficacy in Patient With Unresectable Mesothelioma | NCT05455424 | Mesothelioma, M... | Niraparib Oral ... Active Symptom ... | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). | NCT03946670 | Myelodysplastic... | MBG453 Placebo Hypomethylating... | 18 Years - | Novartis | |
| Neoadjuvant Pazopanib in Renal Cell Carcinoma | NCT01361113 | Renal Cell Carc... | Pazopanib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT01412229 | Head and Neck C... | Cetuximab Nab-paclitaxel Carboplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma | NCT00744640 | Locally Advance... Metastatic Panc... | gemcitabine, ox... | 18 Years - | University Hospital, Basel, Switzerland | |
| Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung | NCT02485652 | Non Small Cell ... | HM61713 | 20 Years - | Hanmi Pharmaceutical Company Limited | |
| Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. | NCT03944304 | Gastrointestina... | Paclitaxel | 20 Years - | Asan Medical Center | |
| Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) | NCT03150004 | Acute Myeloid L... Myelodysplastic... | Cladribine, Cyt... Cladribine and ... | 18 Years - | Medical College of Wisconsin | |
| EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer | NCT02183870 | Lung Cancer Adenocarcinoma NSCLC | Crizotinib | 18 Years - | University of Cologne | |
| A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients | NCT03145961 | Triple Negative... | Pembrolizumab | 16 Years - | Institute of Cancer Research, United Kingdom | |
| Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT01853644 | Recurrent Epith... Recurrent Fallo... Recurrent Prima... | Tivozanib | 18 Years - 110 Years | Northwestern University | |
| Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP | NCT00565370 | Advanced Gastri... | Capecitabine, C... | 18 Years - 75 Years | Asan Medical Center | |
| Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) | NCT00722592 | Ovarian Cancer | Vintafolide pegylated lipos... EC20 | 18 Years - | Endocyte | |
| A Study of Famitinib in Patients With Advanced Colorectal Cancer | NCT01762293 | Colorectal Canc... Colorectal Canc... Colorectal Canc... | Famitinib placebo | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers | NCT05846789 | Metastatic Brea... Triple Negative... Estrogen-recept... | Carboplatin Tocilizumab | 18 Years - | Indiana University | |
| 1st Line Durvalumab in PS 2 NSCLC Patients | NCT03620669 | NSCLC Stage IV NSCLC Stage III... | Durvalumab | 18 Years - | Swiss Group for Clinical Cancer Research | |
| STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS | NCT04878432 | Myelodysplastic... | MBG453 Azacitidine Decitabine INQOVI (oral de... | 18 Years - 99 Years | Novartis | |
| Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers | NCT05846789 | Metastatic Brea... Triple Negative... Estrogen-recept... | Carboplatin Tocilizumab | 18 Years - | Indiana University | |
| 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma | NCT00114309 | Malignant Gliom... Glioblastoma Mu... GBM Anaplastic Astr... Oligo-Astrocyto... Gliosarcoma | 131-I-TM-601 131I-TM601 | 18 Years - | TransMolecular | |
| Neoadjuvant Pazopanib in Renal Cell Carcinoma | NCT01361113 | Renal Cell Carc... | Pazopanib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease | NCT00374296 | Myelogenous Leu... Myelodysplastic... | MGCD0103 | 18 Years - | Mirati Therapeutics Inc. | |
| Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT01829503 | Acute Myeloid L... | decitabine and ... Supportive Care | 60 Years - | University of Pittsburgh |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
